Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency between 2014 and 2017.

Maliepaard M, Toiviainen T, De Bruin ML, Meulendijks D.

Clin Pharmacol Ther. 2020 Mar 31. doi: 10.1002/cpt.1834. [Epub ahead of print]

PMID:
32236952
2.

Behaviour Change Techniques Associated with Smoking Cessation in Intervention and Comparator Groups of Randomised Controlled Trials: A Systematic Review and Meta-Regression.

Black N, Johnston M, Michie S, Hartmann-Boyce J, West R, Viechtbauer W, Eisma MC, Scott C, de Bruin M.

Addiction. 2020 Mar 20. doi: 10.1111/add.15056. [Epub ahead of print] Review.

PMID:
32196796
3.

Publication rates and reported results in a cohort of gene- and cell-based therapy trials.

Coppens DG, Gardarsdottir H, van den Bogert CA, De Bruin ML, Leufkens HG, Hoekman J.

Regen Med. 2020 Jan;15(1):1215-1227. doi: 10.2217/rme-2019-0066. Epub 2020 Feb 27.

PMID:
32103712
4.

Behavioural Determinants of Hand Washing and Glove Recontamination before Aseptic Procedures at Birth: A Time-and-Motion Study and Survey in Zanzibar Labour Wards.

Gon G, Virgo S, de Barra M, Ali SM, Campbell OM, Graham WJ, Nash S, Woodd SL, de Bruin M.

Int J Environ Res Public Health. 2020 Feb 24;17(4). pii: E1438. doi: 10.3390/ijerph17041438.

5.

Variability and effectiveness of comparator group interventions in smoking cessation trials: a systematic review and meta-analysis.

Black N, Eisma MC, Viechtbauer W, Johnston M, West R, Hartmann-Boyce J, Michie S, de Bruin M.

Addiction. 2020 Feb 11. doi: 10.1111/add.14969. [Epub ahead of print] Review.

PMID:
32043675
6.

A systematic review of UK-based long-term nonsurgical interventions for people with severe obesity (BMI ≥35 kg m-2 ).

Aceves-Martins M, Robertson C, Cooper D, Avenell A, Stewart F, Aveyard P, de Bruin M; REBALANCE team.

J Hum Nutr Diet. 2020 Feb 6. doi: 10.1111/jhn.12732. [Epub ahead of print] Review.

PMID:
32027072
7.

Underreporting of the active content of behavioural interventions: a systematic review and meta-analysis of randomised trials of smoking cessation interventions.

de Bruin M, Black N, Javornik N, Viechtbauer W, Eisma MC, Hartman-Boyce J, Williams AJ, West R, Michie S, Johnston M.

Health Psychol Rev. 2020 Jan 13:1-19. doi: 10.1080/17437199.2019.1709098. [Epub ahead of print]

PMID:
31906781
8.

Do pharmacy intervention reports adequately describe their interventions? A template for intervention description and replication analysis of reports included in a systematic review.

de Barra M, Scott C, Johnston M, De Bruin M, Scott N, Matheson C, Bond C, Watson M.

BMJ Open. 2019 Dec 19;9(12):e025511. doi: 10.1136/bmjopen-2018-025511.

9.

Effects of short- and long-acting beta-agonists on asthma exacerbations: a prospective cohort.

Van Ganse E, Texier N, Dima AL, Belhassen M, Laforest L, Herbage S, Schuck S, Hernandez G, Garin O, Ferrer M, de Bruin M; ASTRO-LAB group.

Ann Allergy Asthma Immunol. 2020 Mar;124(3):254-260. doi: 10.1016/j.anai.2019.12.012. Epub 2019 Dec 17.

PMID:
31862434
10.

Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study.

Dima AL, van Ganse E, Stadler G, de Bruin M; ASTRO-LAB group; Members of the ASTRO-LAB group were:.

Eur Respir J. 2019 Dec 19;54(6). pii: 1900901. doi: 10.1183/13993003.00901-2019. Print 2019 Dec.

PMID:
31601714
11.

Acceptability and feasibility of weight management programmes for adults with severe obesity: a qualitative systematic review.

Skea ZC, Aceves-Martins M, Robertson C, De Bruin M, Avenell A; REBALANCE team.

BMJ Open. 2019 Sep 11;9(9):e029473. doi: 10.1136/bmjopen-2019-029473.

12.

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study.

Ibáñez L, Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Heeke A, Huerta C, Martin Merino E, Montero D, Leon-Muñoz LM, Gasse C, Moore N, Droz C, Lassalle R, Aakjaer M, Andersen M, De Bruin ML, Groenwold R, van den Ham HA, Souverein P, Klungel O, Gardarsdottir H.

Br J Clin Pharmacol. 2019 Nov;85(11):2524-2539. doi: 10.1111/bcp.14071. Epub 2019 Sep 4.

13.

The effectiveness of direct to healthcare professional communication - A systematic review of communication factor studies.

Møllebæk M, Kaae S, De Bruin ML, Callréus T, Jossan S, Hallgreen CE.

Res Social Adm Pharm. 2019 May;15(5):475-482. doi: 10.1016/j.sapharm.2018.06.015. Epub 2018 Jun 21.

PMID:
31130181
14.

Body of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016.

Nøhr-Nielsen A, De Bruin ML, Thomsen M, Pipper CB, Lange T, Bjerrum OJ, Lund TM.

Br J Clin Pharmacol. 2019 Aug;85(8):1829-1840. doi: 10.1111/bcp.13986. Epub 2019 Jun 17.

PMID:
31077427
15.

The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.

Klein K, Stolk P, De Bruin ML, Leufkens HGM, Crommelin DJA, De Vlieger JSB.

Eur J Pharm Sci. 2019 May 15;133:228-235. doi: 10.1016/j.ejps.2019.03.029. Epub 2019 Apr 3. Review.

16.

Experiences of gender-based violence among female sex workers, men who have sex with men, and transgender women in Latin America and the Caribbean: a qualitative study to inform HIV programming.

Evens E, Lanham M, Santi K, Cooke J, Ridgeway K, Morales G, Parker C, Brennan C, de Bruin M, Desrosiers PC, Diaz X, Drago M, McLean R, Mendizabal M, Davis D, Hershow RB, Dayton R.

BMC Int Health Hum Rights. 2019 Mar 5;19(1):9. doi: 10.1186/s12914-019-0187-5.

17.

Adjusting for unmeasured confounding using validation data: Simplified two-stage calibration for survival and dichotomous outcomes.

Hjellvik V, De Bruin ML, Samuelsen SO, Karlstad Ø, Andersen M, Haukka J, Vestergaard P, de Vries F, Furu K.

Stat Med. 2019 Jul 10;38(15):2719-2734. doi: 10.1002/sim.8131. Epub 2019 Mar 3.

PMID:
30828842
18.
19.

EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.

Hernandez G, Garin O, Dima AL, Pont A, Martí Pastor M, Alonso J, Van Ganse E, Laforest L, de Bruin M, Mayoral K, Serra-Sutton V, Ferrer M; ASTRO-LAB Group.

J Med Internet Res. 2019 Jan 23;21(1):e10178. doi: 10.2196/10178.

20.

Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study.

Jelvehgaran P, Alderliesten T, Georgiou G, Meijer SL, Bloemen PR, Kodach LL, van Laarhoven HWM, van Berge Henegouwen MI, Hulshof MCCM, Rasch CRN, van Leeuwen TG, de Boer JF, de Bruin M, van Herk M.

Biomed Opt Express. 2018 Aug 14;9(9):4196-4216. doi: 10.1364/BOE.9.004196. eCollection 2018 Sep 1.

21.

Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma.

Opstal-van Winden AWJ, de Haan HG, Hauptmann M, Schmidt MK, Broeks A, Russell NS, Janus CPM, Krol ADG, van der Baan FH, De Bruin ML, van Eggermond AM, Dennis J, Anton-Culver H, Haiman CA, Sawyer EJ, Cox A, Devilee P, Hooning MJ, Peto J, Couch FJ, Pharoah P, Orr N, Easton DF, Aleman BMP, Strong LC, Bhatia S, Cooke R, Robison LL, Swerdlow AJ, van Leeuwen FE.

Blood. 2019 Mar 7;133(10):1130-1139. doi: 10.1182/blood-2018-07-862607. Epub 2018 Dec 20.

23.

Links Between Behavior Change Techniques and Mechanisms of Action: An Expert Consensus Study.

Connell LE, Carey RN, de Bruin M, Rothman AJ, Johnston M, Kelly MP, Michie S.

Ann Behav Med. 2019 Jul 17;53(8):708-720. doi: 10.1093/abm/kay082.

24.

Behavior Change Techniques and Their Mechanisms of Action: A Synthesis of Links Described in Published Intervention Literature.

Carey RN, Connell LE, Johnston M, Rothman AJ, de Bruin M, Kelly MP, Michie S.

Ann Behav Med. 2019 Jul 17;53(8):693-707. doi: 10.1093/abm/kay078.

25.

Hands washing, glove use, and avoiding recontamination before aseptic procedures at birth: A multicenter time-and-motion study conducted in Zanzibar.

Gon G, de Bruin M, de Barra M, Ali SM, Campbell OM, Graham WJ, Juma M, Nash S, Kilpatrick C, Penn-Kekana L, Virgo S, Woodd S.

Am J Infect Control. 2019 Feb;47(2):149-156. doi: 10.1016/j.ajic.2018.07.021. Epub 2018 Oct 4.

26.

Cost-effectiveness and Cost-utility of the Adherence Improving Self-management Strategy in Human Immunodeficiency Virus Care: A Trial-based Economic Evaluation.

Wijnen BFM, Oberjé EJM, Evers SMAA, Prins JM, Nobel HE, van Nieuwkoop C, Veenstra J, Pijnappel FJ, Kroon FP, van Zonneveld L, van Hulzen AGW, van Broekhuizen M, de Bruin M.

Clin Infect Dis. 2019 Feb 1;68(4):658-667. doi: 10.1093/cid/ciy553.

PMID:
30239629
27.

Enhancing Behavior Change Technique Coding Methods: Identifying Behavioral Targets and Delivery Styles in Smoking Cessation Trials.

Black N, Williams AJ, Javornik N, Scott C, Johnston M, Eisma MC, Michie S, Hartmann-Boyce J, West R, Viechtbauer W, de Bruin M.

Ann Behav Med. 2019 May 3;53(6):583-591. doi: 10.1093/abm/kay068.

28.

Pharmacist services for non-hospitalised patients.

de Barra M, Scott CL, Scott NW, Johnston M, de Bruin M, Nkansah N, Bond CM, Matheson CI, Rackow P, Williams AJ, Watson MC.

Cochrane Database Syst Rev. 2018 Sep 4;9:CD013102. doi: 10.1002/14651858.CD013102. Review.

29.

Impact of asthma on women and men: Comparison with the general population using the EQ-5D-5L questionnaire.

Hernandez G, Dima AL, Pont À, Garin O, Martí-Pastor M, Alonso J, Van Ganse E, Laforest L, de Bruin M, Mayoral K, Ferrer M; ASTRO-LAB group.

PLoS One. 2018 Aug 23;13(8):e0202624. doi: 10.1371/journal.pone.0202624. eCollection 2018.

30.

Beliefs about back pain and pain management behaviours, and their associations in the general population: A systematic review.

Morton L, de Bruin M, Krajewska M, Whibley D, Macfarlane GJ.

Eur J Pain. 2019 Jan;23(1):15-30. doi: 10.1002/ejp.1285. Epub 2018 Aug 7.

31.

Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study.

Bloem LT, Mantel-Teeuwisse AK, Leufkens HGM, De Bruin ML, Klungel OH, Hoekman J.

Clin Pharmacol Ther. 2019 Feb;105(2):426-435. doi: 10.1002/cpt.1169. Epub 2018 Aug 12.

PMID:
29969839
32.

Ablation energies for focal treatment of prostate cancer.

Lodeizen O, de Bruin M, Eggener S, Crouzet S, Ghai S, Varkarakis I, Katz A, Dominguez-Escrig JL, Pahernik S, de Reijke T, de la Rosette J.

World J Urol. 2019 Mar;37(3):409-418. doi: 10.1007/s00345-018-2364-x. Epub 2018 Jun 25. Review.

33.

Explaining the Amount and Consistency of Medical Care and Self-Management Support in Asthma: A Survey of Primary Care Providers in France and the United Kingdom.

de Bruin M, Dima AL, Texier N, van Ganse E; ASTRO-LAB group.

J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):1916-1925.e7. doi: 10.1016/j.jaip.2018.04.039. Epub 2018 May 9.

PMID:
29753036
34.

A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.

Coppens DGM, de Wilde S, Guchelaar HJ, De Bruin ML, Leufkens HGM, Meij P, Hoekman J.

Cytotherapy. 2018 Jun;20(6):769-778. doi: 10.1016/j.jcyt.2018.03.038. Epub 2018 May 2.

PMID:
29730080
35.

Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK.

de Jong RGPJ, Peeters PJHL, Burden AM, de Bruin ML, Haak HR, Masclee AAM, de Vries F, Janssen-Heijnen MLG.

Cancer Epidemiol. 2018 Jun;54:104-111. doi: 10.1016/j.canep.2018.04.008. Epub 2018 May 16.

PMID:
29705628
36.

EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.

de Wilde S, Coppens DGM, Hoekman J, de Bruin ML, Leufkens HGM, Guchelaar HJ, Meij P.

Drug Discov Today. 2018 Jul;23(7):1328-1333. doi: 10.1016/j.drudis.2018.03.008. Epub 2018 Mar 21. Review.

37.

Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction.

Rietbergen C, Stefansdottir G, Leufkens HG, Knol MJ, De Bruin ML, Klugkist I.

Front Med (Lausanne). 2018 Feb 22;4:228. doi: 10.3389/fmed.2017.00228. eCollection 2017.

38.

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.

Bronsveld HK, De Bruin ML, Wesseling J, Sanders J, Hofland I, Jensen V, Bazelier MT, Ter Braak B, de Boer A, Vestergaard P, Schmidt MK.

BMC Cancer. 2018 Feb 27;18(1):224. doi: 10.1186/s12885-018-4072-8.

39.

Visibility of fiducial markers used for image-guided radiation therapy on optical coherence tomography for registration with CT: An esophageal phantom study.

Jelvehgaran P, Alderliesten T, Weda JJA, de Bruin M, Faber DJ, Hulshof MCCM, van Leeuwen TG, van Herk M, de Boer JF.

Med Phys. 2017 Dec;44(12):6570-6582. doi: 10.1002/mp.12624. Epub 2017 Nov 6.

PMID:
29023771
40.

Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation.

Coppens DGM, De Bruin ML, Leufkens HGM, Hoekman J.

Clin Pharmacol Ther. 2018 Jan;103(1):120-127. doi: 10.1002/cpt.894. Epub 2017 Nov 6. Review.

PMID:
28983911
41.

When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection.

Klein K, Scholl JHG, De Bruin ML, van Puijenbroek EP, Leufkens HGM, Stolk P.

Clin Pharmacol Ther. 2018 Feb;103(2):296-303. doi: 10.1002/cpt.879. Epub 2017 Oct 25.

PMID:
28913827
42.

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.

Krul IM, Opstal-van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, De Bruin ML, Hauptmann M, Krol ADG, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, van der Maazen RWM, Kesminiene A, Diallo I, de Vathaire F, Russell NS, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):843-853. doi: 10.1016/j.ijrobp.2017.07.016. Epub 2017 Jul 18.

PMID:
28888722
43.

Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.

van Eggermond AM, Schaapveld M, Janus CP, de Boer JP, Krol AD, Zijlstra JM, van der Maazen RW, Kremer LC, van Leerdam ME, Louwman MW, Visser O, De Bruin ML, Aleman BM, van Leeuwen FE.

Br J Cancer. 2017 Jul 25;117(3):306-314. doi: 10.1038/bjc.2017.177. Epub 2017 Jun 20.

44.

Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study.

But A, De Bruin ML, Bazelier MT, Hjellvik V, Andersen M, Auvinen A, Starup-Linde J, Schmidt MK, Furu K, de Vries F, Karlstad Ø, Ekström N, Haukka J.

Diabetologia. 2017 Sep;60(9):1691-1703. doi: 10.1007/s00125-017-4312-5. Epub 2017 Jun 1.

45.

What are the current challenges of managing cancer pain and could digital technologies help?

Adam R, de Bruin M, Burton CD, Bond CM, Giatsi Clausen M, Murchie P.

BMJ Support Palliat Care. 2018 Jun;8(2):204-212. doi: 10.1136/bmjspcare-2016-001232. Epub 2017 May 29.

46.

Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.

Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X.

Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1442-1450. doi: 10.1002/pds.4196. Epub 2017 Mar 26.

PMID:
28345151
47.

Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.

Bhardwaj R, van der Meer A, Das SK, de Bruin M, Gascon J, Wolterbeek HT, Denkova AG, Serra-Crespo P.

Sci Rep. 2017 Mar 13;7:44242. doi: 10.1038/srep44242.

48.

Predicting adherence to combination antiretroviral therapy for HIV in Tanzania: A test of an extended theory of planned behaviour model.

Banas K, Lyimo RA, Hospers HJ, van der Ven A, de Bruin M.

Psychol Health. 2017 Oct;32(10):1249-1265. doi: 10.1080/08870446.2017.1283037. Epub 2017 Feb 13.

PMID:
28276745
49.

Measuring medication adherence in asthma: Development of a novel self-report tool.

Dima AL, van Ganse E, Laforest L, Texier N, de Bruin M; The Astro-Lab Group.

Psychol Health. 2017 Oct;32(10):1288-1307. doi: 10.1080/08870446.2017.1290248. Epub 2017 Feb 20.

PMID:
28276742
50.

Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.

de Bruin M, Oberjé EJM, Viechtbauer W, Nobel HE, Hiligsmann M, van Nieuwkoop C, Veenstra J, Pijnappel FJ, Kroon FP, van Zonneveld L, Groeneveld PHP, van Broekhuizen M, Evers SMAA, Prins JM.

Lancet Infect Dis. 2017 Jun;17(6):595-604. doi: 10.1016/S1473-3099(16)30534-5. Epub 2017 Mar 3.

PMID:
28262598

Supplemental Content

Loading ...
Support Center